A multi-centre, randomized, controlled, single-blinded, phase II study to investigate the safety and efficacy of intravenous infusions of FERINJECT® versus placebo in patients with thrombocytosis secondary to iron deficiency and chronic inflammatory bowel disease - ThromboVIT

Vifor Int.0 个研究点开始时间: 2006年11月24日最近更新: 2012年11月19日

适应症

试验速览

暂无简介。

•1.Male or female, inpatient or outpatient, aged at least 16 years and not more than 60 years.
•2.platelet count >450G/l
•3.Transferrin saturation (TfS) <20% or ferritin < 100?g/l
•4.Previously diagnosed inflammatory bowel disease (Crohn’s disease or ulcerative colitis)
•Are the trial subjects under 18? yes
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•1.CDAI >220 9, CAI>6 10
•2.Significant anemia (hemoglobin <10.5 g/dl)
•3.Blood transfusions or iron therapy during the previous 4 weeks, or erythropoietin treatment within the 8 weeks prior to enrolment.

发起方

Vifor Int.